TriangleDISEASE & TREATMENT SETTING
Thyroid Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Thyroid Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Thyroid Cancer. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
11 more-specific settings
Mekinist: metastatic Thyroid Cancer with BRAF V600E →Thyrogen: metastatic Thyroid Cancer →Tafinlar: metastatic Thyroid Cancer with BRAF V600E →Lenvima: metastatic Thyroid Cancer →COMETRIQ: metastatic Thyroid Cancer →Nexavar: metastatic Thyroid Carcinoma →CAPRELSA: unresectable metastatic Thyroid Cancer →localized Thyroid Cancer →metastatic Thyroid Cancer →recurrent Thyroid Cancer →Stage IV Thyroid Cancer →
Study evidence for this setting
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Project HERO: Health Empowerment & Recovery Outcomes
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Fact
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Indication-specific source history
2020-05-08 · Retevmo (selpercatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-71a184400881623a
- event date
- 2020-05-08
- event kind
- accelerated-approval
- drug or regimen
- Retevmo (selpercatinib)
- source indication text
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-34303ef4a0f5d9da66ed
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-05-08 · Retevmo (selpercatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-e073a86346d84dba
- event date
- 2020-05-08
- event kind
- accelerated-approval
- drug or regimen
- Retevmo (selpercatinib)
- source indication text
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-72ab3fa819df036d6fb3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-12-01 · Gavreto (pralsetinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-00745d46cd62c1e5
- event date
- 2020-12-01
- event kind
- accelerated-approval
- drug or regimen
- Gavreto (pralsetinib)
- source indication text
- Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b86c12dadbbbf05b6c82
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-12-01 · Gavreto (pralsetinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-1c569388cc164e61
- event date
- 2020-12-01
- event kind
- accelerated-approval
- drug or regimen
- Gavreto (pralsetinib)
- source indication text
- Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-aa53a9ab79697a07fa63
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-07-20 · Gavreto (pralsetinib) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-cc1d19d9ed25e7bb
- event date
- 2023-07-20
- event kind
- withdrawal
- drug or regimen
- Gavreto (pralsetinib)
- source indication text
- Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-aa53a9ab79697a07fa63
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-06-12 · Retevmo (selpercatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-793cb8998d22b54f
- event date
- 2024-06-12
- event kind
- traditional-approval
- drug or regimen
- Retevmo (selpercatinib)
- source indication text
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-72ab3fa819df036d6fb3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-09-27 · Retevmo (selpercatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- event id
- fda-21c5c4e24dbcccf8
- event date
- 2024-09-27
- event kind
- traditional-approval
- drug or regimen
- Retevmo (selpercatinib)
- source indication text
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *
- match phrase
- thyroid cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-34303ef4a0f5d9da66ed
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-thyroid-cancer
- binding id
- ncit-C4815
- source collection
- ncit-concept
- source key
- C4815
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice